645 related articles for article (PubMed ID: 26258849)
21. A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
Siriwardena SU; Perera MLW; Senevirathne V; Stewart J; Bhagwat AS
Mol Cell Biol; 2019 Jan; 39(1):. PubMed ID: 30348839
[TBL] [Abstract][Full Text] [Related]
22. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
[TBL] [Abstract][Full Text] [Related]
23. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
24. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.
Taylor BJ; Nik-Zainal S; Wu YL; Stebbings LA; Raine K; Campbell PJ; Rada C; Stratton MR; Neuberger MS
Elife; 2013 Apr; 2():e00534. PubMed ID: 23599896
[TBL] [Abstract][Full Text] [Related]
25. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
26. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
27. Repair of multiple simultaneous double-strand breaks causes bursts of genome-wide clustered hypermutation.
Sakofsky CJ; Saini N; Klimczak LJ; Chan K; Malc EP; Mieczkowski PA; Burkholder AB; Fargo D; Gordenin DA
PLoS Biol; 2019 Sep; 17(9):e3000464. PubMed ID: 31568516
[TBL] [Abstract][Full Text] [Related]
28. BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.
Coelho MA; Li S; Pane LS; Firth M; Ciotta G; Wrigley JD; Cuomo ME; Maresca M; Taylor BJM
BMC Biol; 2018 Dec; 16(1):150. PubMed ID: 30593278
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme.
Caval V; Bouzidi MS; Suspène R; Laude H; Dumargne MC; Bashamboo A; Krey T; Vartanian JP; Wain-Hobson S
Nucleic Acids Res; 2015 Oct; 43(19):9340-9. PubMed ID: 26384561
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context.
Seplyarskiy VB; Andrianova MA; Bazykin GA
Genome Res; 2017 Feb; 27(2):175-184. PubMed ID: 27940951
[TBL] [Abstract][Full Text] [Related]
31. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3B mutagenesis in cancer.
Kuong KJ; Loeb LA
Nat Genet; 2013 Sep; 45(9):964-5. PubMed ID: 23985681
[TBL] [Abstract][Full Text] [Related]
34. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
[TBL] [Abstract][Full Text] [Related]
35. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion.
Nowarski R; Kotler M
Cancer Res; 2013 Jun; 73(12):3494-8. PubMed ID: 23598277
[TBL] [Abstract][Full Text] [Related]
37. Evidence for APOBEC3B mutagenesis in multiple human cancers.
Burns MB; Temiz NA; Harris RS
Nat Genet; 2013 Sep; 45(9):977-83. PubMed ID: 23852168
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3B cytidine deaminase targets the non-transcribed strand of tRNA genes in yeast.
Saini N; Roberts SA; Sterling JF; Malc EP; Mieczkowski PA; Gordenin DA
DNA Repair (Amst); 2017 May; 53():4-14. PubMed ID: 28351647
[TBL] [Abstract][Full Text] [Related]
39. Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
Brachova P; Alvarez NS; Van Voorhis BJ; Christenson LK
Gynecol Oncol; 2017 Jun; 145(3):577-583. PubMed ID: 28215840
[TBL] [Abstract][Full Text] [Related]
40. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
